Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has temporarily halted recruitment and dosing in three clinical studies of its ...

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

“There are no disease-modifying treatments approved for patients with any subtype of limb-girdle muscular dystrophy ... of research and development, Sarepta Therapeutics.

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Shares of Sarepta Therapeutics plunged following the March announcement ... The company reported March 18 that a patient with Duchenne muscular dystrophy who was taking Elevidys died of acute liver ...

Sarepta Therapeutics said Tuesday that a patient ... gene therapy delandistrogene moxeparvovec in a rat model of Duchenne muscular dystrophy (DMD). A Phase 3 clinical trial investigating Elevidys ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

April 15, 2025--(BUSINESS WIRE)--Sarepta Therapeutics ... updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4.

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

April 15, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on ...